What Microdosing Is
A microdose is typically defined as approximately one-tenth to one-twentieth of a standard psychoactive dose. The most commonly used substances are psilocybin mushrooms and LSD, though mescaline, DMT, and others are also used.
Microdosing was originally characterised as "sub-perceptual" — the idea being that an effective dose would produce no noticeable psychoactive effects whatsoever. This framing, popularised by early proponents such as James Fadiman, was intended to distinguish microdosing from a full psychedelic experience. However, it contains a notable internal contradiction: if a substance produces literally no perceptible effect, it is difficult to explain why it would produce any meaningful benefit. The more accurate and useful framing, increasingly supported by practitioner experience and emerging research, is that microdosing involves a dose range where mild, functional perceptual effects — a slight brightening of mood, heightened sensory sensitivity, a subtle shift in perspective — are not only normal but may be part of how the practice works. The intention is not a full psychedelic journey; it is a low, manageable dose that can be integrated into ordinary daily functioning.
Practitioners report subtle to mild shifts in mood, emotional regulation, creativity, focus, and sense of connection. The practice has spread most visibly through technology and creative industries, though its advocates span a wide range of backgrounds and intentions.
Evidence note — read this first
Microdosing is one of the most hyped and least substantiated practices in the contemporary psychedelic landscape. Blinded, placebo-controlled studies have produced mixed results, with expectation effects accounting for a substantial portion of self-reported benefits. This page aims to represent the evidence honestly, including its limitations.
What the Evidence Actually Shows
The expectation problem
The most consistent finding in controlled microdosing research is how difficult it is to separate genuine pharmacological effects from expectation. Szigeti and colleagues (2021) conducted the first self-blinded citizen science study and found that microdosers who correctly identified whether they had taken the active substance reported substantially larger benefits than those who did not — suggesting expectation plays a major mediating role.
Pre-registered placebo-controlled trials
Szigeti et al. (2021) found improvements in psychological well-being in the microdose condition, but noted significant unblinding. Cavanna and colleagues (2022) found no significant cognitive enhancement in a double-blind study. Szigeti's follow-up work and studies by Szigeti, Erritzoe, and Nutt generally find modest positive effects on mood and well-being that are difficult to cleanly disentangle from placebo response.
What the evidence does not show
Microdosing has not been demonstrated to reliably enhance cognitive performance (attention, memory, executive function) in controlled conditions. Claims about dramatic productivity improvements, neurogenesis, or significant antidepressant effects from microdosing alone are not currently supported by the evidence.
What remains genuinely uncertain
This does not mean microdosing has no real effects. Low-level serotonergic activity at these dose ranges is biologically plausible, and individual variation is real. The honest position is: the evidence is preliminary, expectation effects are substantial, and individual responses vary considerably.
Psygaia perspective
The discourse around microdosing reflects a broader pattern in the psychedelic renaissance — genuine phenomena being over-interpreted through frameworks of individual productivity and cognitive enhancement, at the expense of relational, ecological, and collective dimensions. The Psygaia Framework offers a complementary lens.
Common Protocols
The Fadiman Protocol
Developed by psychologist James Fadiman, the most widely used microdosing protocol: one day on, two days off, repeating for four to eight weeks, followed by a break. The rationale for the rest days is to prevent tolerance development and preserve the contrast between microdose days and baseline, which aids accurate self-assessment.
The Stamets Stack
Developed by mycologist Paul Stamets: psilocybin mushrooms combined with lion's mane mushroom (hericium erinaceus) and niacin (vitamin B3), taken on a four-days-on, three-days-off cycle. The combination is theorised to enhance neuroplasticity — though this specific stack has not been studied in controlled trials. The niacin is included for its proposed role in facilitating the delivery of psilocybin and lion's mane to peripheral neurons.
Every-other-day protocol
Some practitioners use an every-other-day schedule. Less common and carries a slightly higher risk of gradual tolerance accumulation.
Tracking your experience
Whatever protocol you use, keeping a daily journal — noting mood, energy, focus, sleep, social connection, and any perceptual shifts — is valuable both for personal calibration and for catching any emerging downsides early. If you are not noticing improvement within four to six weeks, that is important information.
Substances Used in Microdosing
Psilocybin mushrooms are the most commonly used substance. Typical microdose range is 0.05–0.3 g of dried mushrooms (P. cubensis), though potency varies considerably by strain and growing conditions, making consistent dosing genuinely difficult. Many practitioners use capsules filled with finely ground dried mushroom for more consistent dosing.
LSD is the second most common. Typical microdose range is 5–20 micrograms. LSD's longer duration (8–12 hours) means microdose effects can extend well into the evening, which some find disruptive to sleep. LSD's reliable, measurable concentration in solution (volumetric dosing) makes it easier to dose precisely than mushrooms.
1P-LSD and other LSD analogues were widely used while legal — their status varies by jurisdiction. Assume the same risks and interactions as LSD.
Risks and Important Cautions
Anxiety amplification. Microdosing can amplify pre-existing anxiety rather than reducing it, particularly in people who are anxious about the practice itself or who are in an unsettled period of life.
Cardiac considerations. Chronic low-level serotonergic agonism has theoretical risks for heart valve integrity with long-term use — based on analogy with other serotonin agonists. This has not been demonstrated in microdosing research specifically, but is a consideration for anyone planning to microdose consistently over extended periods.
Contraindications mirror full-dose contraindications. Personal or family history of schizophrenia spectrum disorders or bipolar I is a meaningful caution even at low doses. SSRIs will blunt or block effects.
Legal status. In most jurisdictions, psilocybin and LSD remain controlled substances regardless of dose. Microdosing is not a legal workaround.
Dependence risk is low for classical psychedelics due to their serotonergic tolerance mechanism. But psychological reliance — using microdosing as a crutch rather than a complement to other practices — is worth watching for.
An Ecological Perspective on Microdosing
The dominant framing of microdosing — productivity tool, cognitive enhancer, mood hack — reflects the individualistic, performance-oriented values of the technological contexts that popularised it. This framing is not necessarily wrong, but it is partial.
A different question worth asking: what might low-dose, sustained engagement with psychedelic organisms do to one's attunement to the living world, to one's relationships, and to one's sense of embeddedness in something larger than individual performance? Practitioners who approach microdosing through an ecological or relational lens — alongside time in nature, contemplative practice, and community engagement — tend to report qualitatively different experiences than those approaching it as a productivity intervention.
This does not mean microdosing causes ecological attunement. It means that what we bring to a practice shapes what we receive from it — which applies as much at low doses as at full ones.
Frequently Asked Questions
How do I start microdosing for the first time? +
Start by doing your research before obtaining anything: understand your local legal situation, any personal medical contraindications, and your intentions. Once you have a substance, choose a starting dose on the low end of the range (0.1 g of dried psilocybin mushrooms or 5–10 mcg of LSD). Pick a structured protocol — the Fadiman Protocol (one day on, two days off) is the most beginner-friendly. Begin on a day with no high-stakes obligations: no driving, no childcare, no critical meetings. Keep a daily journal from Day 1, including off days. Avoid combining with other substances, especially cannabis or alcohol, until you understand your baseline response. Give yourself a full 4–6 week cycle before drawing any conclusions.
How do I find the right dose for me? +
There is no universally correct dose, because individual sensitivity and substance potency both vary. For psilocybin mushrooms, a common starting range is 0.1–0.3 g of dried Psilocybe cubensis; for LSD, 5–20 mcg. The principle is "start low, go slow." Begin at the lower end and only adjust between full cycles — not mid-cycle — in small increments. The goal is the lowest dose at which you notice any meaningful functional shift. If you feel clearly impaired, anxious, or noticeably altered, the dose is too high. If nothing at all happens over several weeks of consistent journalling, you may be under-dosing or, if you take an SSRI, your receptor activity may be blunted.
How do I measure psilocybin mushrooms accurately? +
Accurate measurement requires a milligram-precise scale (accurate to 0.01 g — standard kitchen scales are not adequate). Potency also varies considerably between mushroom batches, strains, and even individual mushrooms within the same bag. The most practical solution is to grind your entire batch into a fine, homogeneous powder and mix it thoroughly before weighing individual doses — this averages out variability across the batch. Filling capsules with pre-weighed doses is a popular approach for consistency and to avoid taste. Do not try to visually estimate doses; physical appearance is not a reliable indicator of potency.
How often should I microdose? Can I do it every day? +
Daily microdosing is strongly discouraged. Classical psychedelics build pharmacological tolerance quickly — within two to three consecutive days of use, the same dose produces substantially diminished effects. The two most widely used protocols both build in mandatory off days for this reason: the Fadiman Protocol doses once every three days, and the Stamets Protocol doses five days on and two days off. After a full 4–8 week cycle, taking a two to four week full break before starting another cycle is standard practice. Some experienced practitioners eventually transition to an "intuitive" approach — dosing as needed, never two consecutive days — but this is not recommended for beginners.
How long does a microdose last? +
Duration varies by substance. A psilocybin microdose typically begins to take effect 30–60 minutes after ingestion and lasts 4–6 hours, making it compatible with a full working day if taken in the morning. An LSD microdose begins within 30–90 minutes and lasts 8–12 hours — meaning if taken after mid-morning it can disrupt sleep, which is one reason psilocybin is often preferred for daytime use. The lemon tek preparation method for psilocybin speeds onset significantly (to 15–30 minutes) and shortens overall duration, but also intensifies the experience and is not recommended for beginners.
What effects can I realistically expect from microdosing? +
The most commonly reported effects in self-report studies are: improved mood and emotional resilience, reduced anxiety and depressive symptoms, increased focus and clarity, heightened creativity and openness, greater empathy and ease in social situations, and a mild enhancement of sensory awareness. Physical effects some people notice include more energy, improved sleep quality, and reduced headaches — though headaches are also reported as a side effect by others. Effects are typically subtle and cumulative over weeks rather than immediately obvious after a single dose day. It is worth noting that expectancy (the placebo effect) plays a significant role in self-reported benefits — controlled studies find that knowing you are taking an active substance influences outcomes considerably. This does not mean the effects are not real; it means that mindset, intention, and lifestyle context are genuinely part of what microdosing produces.
Does microdosing actually work, or is it mostly placebo? +
The honest answer is: the science remains inconclusive. Observational and self-report studies consistently show that microdosers report improved mood, focus, and wellbeing compared to non-microdosing controls. However, several blinded, placebo-controlled trials have found that many of these benefits shrink considerably when participants do not know whether they received an active substance. A 2021 self-blinding citizen science study (Szigeti et al.) found that expectancy accounted for a substantial portion of reported benefits. Subsequent pre-registered RCTs — including studies at the University of Copenhagen and Imperial College London — have similarly found modest or inconsistent effects over placebo. The current scientific consensus is: low-level pharmacological effects are biologically plausible, individual responses are real and variable, and expectancy effects are substantial. Dramatic claims about reliable cognitive enhancement or antidepressant effects are not supported by controlled evidence. More rigorous trials are underway and the field is evolving quickly.
How do I know if my microdosing is working? +
Keep a daily journal that includes both dose days and off days, noting mood (rate 1–10), energy, focus, social ease, anxiety, sleep, and any notable events or insights. The signal you are looking for is often subtle and cumulative — a general lift in baseline mood over weeks, greater capacity to handle stress, increased curiosity or creativity in daily life — rather than a dramatic change on dose days themselves. After a full 4–6 week cycle, reviewing your journal entries comparatively is far more reliable than going by day-to-day impression. Many people who feel microdosing "isn't working" either have not kept a systematic journal, are dosing too low, or have SSRIs blunting their response.
How do I know if I'm taking the right amount? +
Calibrating a microdose is more nuanced than early guidance suggested. The original definition — that a microdose must be entirely "sub-perceptual," with zero noticeable effect — has been reconsidered. Mild perceptual effects (a slight lift in mood, gentle heightening of sensory awareness, a subtle shift in perspective) are now understood to be a normal and potentially functional part of the practice, not a sign that your dose is too high. What you are aiming to avoid is impairment: significant alterations to concentration, coordination, emotional regulation, or the capacity to function normally in daily life. If you are experiencing strong visual effects, notable anxiety, or difficulty working or socialising, reduce your dose. If you are noticing nothing after several weeks, you may calibrate slightly upward — gradually, and with a journal.
What are the common side effects of microdosing? +
Commonly reported adverse effects include: nausea and gastrointestinal discomfort (particularly with psilocybin, and typically during the onset window), headaches, mild increase in anxiety or overstimulation (especially in people who are already anxious), insomnia if dosed too late in the day (particularly with LSD, given its long duration), and emotional amplification — meaning both positive and negative emotional states may be heightened. A minority of people report worsened mood or increased neuroticism over time, which is a signal to pause and reassess. If you experience significant anxiety, insomnia, or mood worsening across multiple dose cycles, microdosing may not be suitable for you at any dose, or at this time in your life.
Are there long-term risks from microdosing regularly? +
The most significant theorised long-term risk is cardiac valve damage (valvulopathy). Both psilocybin and LSD activate the serotonin 5-HT2B receptor, and chronic activation of this receptor is associated with cardiac fibrosis and heart valve thickening — the same mechanism that led to the withdrawal of the diet drug fenfluramine (Fen-Phen). No human study has yet confirmed this risk at microdosing dose levels, and a mouse study of LSD found no cardiac changes. However, researchers at Harvard's Petrie-Flom Center and in peer-reviewed publications have identified this as a legitimate concern requiring monitoring for anyone microdosing consistently over months. The practical takeaway: follow structured protocols with scheduled full breaks between cycles, and do not microdose indefinitely without pause. Consult a cardiologist if you have any pre-existing cardiac concerns.
Can microdosing cause or worsen anxiety? +
Yes, for some people. Dr. James Fadiman noted in his early research that participants who entered specifically to address anxiety often found that microdosing increased it rather than reduced it. Overstimulation, heightened self-consciousness, or amplification of existing worry is the most common reason people discontinue. If anxiety increases noticeably on dose days, the first step is to reduce the dose rather than stop altogether — many people find a lower dose resolves the issue. Spacing doses further apart can also help. If anxiety persists at any dose, microdosing may not be the right tool for you, at least at this point in time.
Can I microdose if I'm taking SSRIs or other antidepressants? +
This is one of the most frequently asked questions in the microdosing community, and the answer involves several distinct issues. First, blunted effects: SSRIs and SNRIs downregulate 5-HT2A receptors, meaning they reduce or block the effects of psilocybin and LSD — sometimes dramatically. Many people on SSRIs report little or no response even at doses well above a typical microdose. This blunting can persist for weeks to months after stopping an SSRI. Second, serotonin toxicity: combining serotonergic substances carries a theoretical risk of serotonin syndrome, particularly at higher doses; at microdose levels the risk is low but not zero, and certain medication combinations (especially MAOIs) carry serious risk at any dose. Third, medication changes: some people choose to taper off their SSRI to microdose — this must only be done under medical supervision. SSRI discontinuation syndrome is real, can be serious, and some SSRIs (particularly paroxetine and venlafaxine) require particularly careful tapering. Do not abruptly stop a psychiatric medication to microdose.
Are there medications that are absolutely contraindicated with microdosing? +
MAOIs carry the highest risk: combining them with serotonergic psychedelics can cause life-threatening serotonin syndrome. Lithium is considered dangerous in combination with psychedelics based on case reports of seizures. Stimulant medications (Adderall, Ritalin) may have unpredictable interactions. Cardiovascular medications that affect serotonin signalling or heart rhythm require discussion with a prescriber. As a general rule: if you are on any prescription medication, do not begin microdosing without consulting a healthcare provider who understands psychedelic pharmacology.
Who should not microdose? +
Clear contraindications and high-risk situations include: personal or family history of schizophrenia, schizoaffective disorder, or psychotic disorders; bipolar I disorder (risk of triggering manic episodes); active, unstable severe mental illness; current use of MAOIs or lithium; pregnancy or breastfeeding; significant cardiovascular conditions (given the theoretical 5-HT2B cardiac concern); and being under 18. People going through acute crisis, major trauma, or significant emotional instability should also exercise caution — microdosing amplifies emotional states and may not be beneficial during periods of active destabilisation. These are not bureaucratic cautions; they are grounded in real mechanisms of risk.
Can I microdose and go to work normally? +
Many people do — this is one of the defining practical features of microdosing compared to full psychedelic use. A well-calibrated dose should not impair functional capacity. That said, individual sensitivity varies considerably. The first two to three microdose days of any new cycle should be taken on days without high-stakes obligations — important presentations, driving long distances, complex childcare — so you can establish your actual response before integrating the practice into a demanding working day. LSD microdoses can extend well into the evening and may affect sleep; psilocybin's shorter duration (4–6 hours) makes it more compatible with a standard working day.
Should I tell my doctor I'm microdosing? +
If you take any prescription medications — particularly SSRIs, MAOIs, lithium, cardiovascular medications, or stimulants — yes, the interaction considerations are real even at low doses. If you have a pre-existing mental or physical health condition, your doctor should know. In practice, many people are reluctant to disclose due to stigma or legal concerns, which is understandable — but withholding relevant health information from a prescriber increases risk, not reduces it. If your current doctor is unreceptive, seeking a clinician with psychedelic medicine knowledge may be worthwhile.
Is microdosing legal? +
In most of the world, no. Psilocybin and LSD remain Schedule I controlled substances under US federal law and are controlled under the UN 1971 Convention in most countries, meaning possession is illegal regardless of dose. Exceptions as of 2025–2026: Oregon and Colorado have decriminalised psilocybin for adults and established regulated therapeutic frameworks; several US cities (Denver, Oakland, Seattle, Washington D.C., and others) have deprioritised enforcement of personal possession. Internationally, Jamaica, the Netherlands (for truffles), and Brazil have no criminal prohibition. Australia, Canada, and several European countries permit psilocybin in therapeutic or research contexts. Microdosing is not a legal workaround in jurisdictions where the substance itself is controlled — the law applies to the molecule, not the dose.
What's the difference between microdosing psilocybin mushrooms and LSD? +
The main practical differences: Duration — psilocybin lasts 4–6 hours; LSD lasts 8–12 hours, which can disrupt sleep and requires early-morning dosing. Dosing precision — LSD blotters have uneven compound distribution, making precise low-dose measurement difficult; volumetric dosing (dissolving blotter in water and dosing by volume) is required for reliable microdoses. Mushroom potency varies batch-to-batch, requiring careful grinding and mixing. Character — many practitioners describe psilocybin as warmer, more emotionally oriented, and more compatible with introspective work; LSD as more stimulating, cognitively energising, and longer-lasting. For beginners, psilocybin mushrooms are generally recommended first due to shorter duration, more forgiving dose calibration, and considerably more research backing.
Does tolerance build up with microdosing? +
Yes — pharmacological tolerance to classical psychedelics develops rapidly with consecutive use. Using psilocybin or LSD on consecutive days produces noticeably diminished effects by Day 2–3, and near-complete tolerance by Day 4–5. This is why every established microdosing protocol includes mandatory off days and full breaks between cycles: without them, the practice rapidly loses effectiveness. Cross-tolerance also exists between psilocybin, LSD, and mescaline — using one within a few days of the other will blunt the effects. Tolerance resets within approximately one to two weeks of full abstinence. This tolerance mechanism is also why classical psychedelics have a very low addiction profile: compulsive daily use is pharmacologically self-defeating.
Is microdosing addictive? +
Classical psychedelics like psilocybin and LSD do not produce physical dependence and have a very low abuse potential compared to other psychoactive substances. The rapid tolerance mechanism makes compulsive use pharmacologically self-defeating. Psychological dependence — using microdosing as an emotional crutch rather than a complement to other practices and lifestyle changes — is possible in principle, as it is with any behaviour that reliably alters mood. Practitioners and harm reduction frameworks recommend treating microdosing as a time-limited practice with scheduled breaks, rather than an indefinite daily supplement, both to prevent tolerance and to maintain honest self-assessment of whether the practice is serving you.
What is "integration" in the context of microdosing? +
Integration refers to the active process of bringing insights, emotional shifts, or changed perspectives from microdosing into the fabric of daily life — relationships, habits, work, and values. Unlike full psychedelic experiences (which often produce intense material requiring dedicated integration work), microdosing integration is subtler. It tends to involve: daily journalling to notice patterns over time; regular reflection on whether the practice is producing the changes you intended; conversations with a therapist, integration coach, or trusted person who understands the practice; and adjusting lifestyle factors — time in nature, exercise, creative work, social connection — that the microdosing may be making more accessible. The r/microdosing community frequently emphasises that microdosing is a "tool, not a cure" — the practice supports change, but does not replace the work of change itself.
What are the most common mistakes beginners make when microdosing? +
Based on aggregated community experience and harm reduction literature, the most common errors are: (1) Dosing too high — the most frequent mistake, producing an unwanted mildly psychedelic experience rather than a functional one; (2) Not keeping a journal, making it impossible to distinguish genuine patterns from daily variation; (3) Skipping rest days or continuing indefinitely without a full multi-week break; (4) Combining with SSRIs or other medications without understanding the interactions; (5) Starting during a period of crisis or emotional instability — microdosing amplifies emotional states and is not a crisis intervention; (6) Expecting dramatic or immediate results — effects are typically subtle and cumulative over weeks; (7) Sourcing unreliably, leading to inconsistent potency; and (8) Neglecting set and setting — mindset and life context shape outcomes even at low doses.